Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Expert Opinion on Pharmacotherapy|June 24, 2010
Comparison of orlistat treatment and placebo in obese type 2 diabetic patientsGiuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, et al.
Heart and Vessels|May 26, 2009
Oral fat load effects on inflammation and endothelial stress markers in healthy subjectsGiuseppe Derosa, Ilaria Ferrari, Angela D'Angelo, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|April 1, 2009
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemiaGiuseppe Derosa, Pamela Maffioli, Angela D'Angelo, et al.
Microvascular Research|April 3, 2010
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjectsGiuseppe Derosa, Ilaria Ferrari, Angela D'Angelo, et al.
International Journal of General Medicine|July 1, 2021
Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical TrialFrancesco Di Pierro, Somia Iqtadar, Amjad Khan, et al.
Archives of Medical Research|April 1, 2008
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metforminGiuseppe Derosa, Sibilla A T Salvadeo, Angela D'Angelo, et al.
Pharmacological Research|December 4, 2018
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT studyGiuseppe Derosa, Pamela Maffioli, Laura Scelsi, et al.
Frontiers in Pharmacology|January 30, 2023
Quercetin as a possible complementary agent for early-stage COVID-19: Concluding results of a randomized clinical trialFrancesco Di Pierro, Amjad Khan, Somia Iqtadar, et al.
Nutrients|January 11, 2025
Nutraceuticals and Supplements in Management of Prediabetes and DiabetesGiuseppe Derosa, Angela D'Angelo, Fabrizio Angelini, et al.
Metabolism: Clinical and Experimental|December 18, 2009
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patientsGiuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, et al.
Pageof 17